These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23371447)

  • 1. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
    Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orteronel for the treatment of prostate cancer.
    Van Hook K; Huang T; Alumkal JJ
    Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M; Garcia JA
    Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CYP17: established and novel approaches in prostate cancer.
    Yap TA; Carden CP; Attard G; de Bono JS
    Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
    Gupta E; Guthrie T; Tan W
    BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
    Roviello G; Pacifico C; Chiriacò G; Generali D
    Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
    J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
    Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
    Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
    Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
    Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
    Eichholz A; Ferraldeschi R; Attard G; de Bono JS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):68-75. PubMed ID: 21986558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
    Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
    Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
    J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.